Research and Markets: PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vzvsq4/pharmapoint) has announced the addition of GlobalData's new report "PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis" to their offering.

“PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis”

PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

The Japanese influenza vaccine market is valued at approximately $702 million in 2012. The projected drivers for growth of the Japanese influenza vaccine market include the entrance of large, multinational firms into the marketplace, a government commitment to educating the populace about the importance of preventative medicine (including vaccination), and growth of the elderly population. GlobalData does not project that intradermal and intranasal vaccines will enter the Japan market during the forecast period, leaving all market dynamics between existing and new intramuscular vaccines.

The Japanese influenza vaccine market differs from its US or European counter parts due the large role that non-commercial entities play in the marketplace. For example, the Chemo-Sero-Therapeutic Research Institute is the market leader. The organization is also referred to as Kaketsuken (abbreviation of its name in Japanese). Kaketsuken's recent completion of a new influenza vaccine plant, which doubled its production capacity, is an embodiment of the resources and commitment to the influenza vaccines that have enabled it to attain its position in the Japanese market.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Market Outlook

9 Appendix

For more information visit http://www.researchandmarkets.com/research/vzvsq4/pharmapoint

Source: GlobalData